Analysts are on the Bearish side about Envision Healthcare Corporation (NYSE:EVHC) this week.

June 16, 2018 - By Hazel Jackson

Envision Healthcare Corporation (NYSE:EVHC) Ratings Coverage

Among 13 analysts covering Envision Healthcare (NYSE:EVHC), 3 have Buy rating, 0 Sell and 10 Hold. Therefore 23% are positive. Envision Healthcare had 28 analyst reports since December 20, 2017 according to SRatingsIntel. The rating was maintained by SunTrust on Wednesday, February 28 with “Buy”. Raymond James downgraded Envision Healthcare Corporation (NYSE:EVHC) on Tuesday, June 12 to “Market Perform” rating. The firm earned “Neutral” rating on Wednesday, February 28 by Cantor Fitzgerald. The stock of Envision Healthcare Corporation (NYSE:EVHC) earned “Hold” rating by William Blair on Monday, June 11. The firm has “Outperform” rating given on Wednesday, January 31 by Credit Suisse. Canaccord Genuity maintained it with “Buy” rating and $4800 target in Tuesday, May 8 report. Stephens maintained Envision Healthcare Corporation (NYSE:EVHC) rating on Wednesday, February 28. Stephens has “Hold” rating and $43.0 target. The firm has “Buy” rating given on Wednesday, December 20 by SunTrust. SunTrust downgraded the stock to “Hold” rating in Tuesday, June 12 report. The company was maintained on Tuesday, April 10 by Cantor Fitzgerald. Below is a list of Envision Healthcare Corporation (NYSE:EVHC) latest ratings and price target changes.

13/06/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Hold Old Target: $48 New Target: $46 Downgrade
12/06/2018 Broker: Raymond James Old Rating: Strong Buy New Rating: Market Perform Old Target: $51 Downgrade
12/06/2018 Broker: SunTrust Rating: Hold Downgrade
12/06/2018 Broker: RBC Capital Markets Rating: Hold Downgrade
11/06/2018 Broker: Robert W. Baird Rating: Hold Downgrade
11/06/2018 Broker: William Blair Rating: Hold Downgrade
08/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $48.0000 Maintain
07/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $40.0000 Maintain
11/04/2018 Broker: Robert W. Baird Rating: Buy New Target: $50.0000 Maintain
10/04/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $40.0000 Maintain

The stock decreased 0.25% or $0.11 during the last trading session, reaching $44.67. About 7.12M shares traded or 80.10% up from the average. Envision Healthcare Corporation (NYSE:EVHC) has declined 22.24% since June 16, 2017 and is downtrending. It has underperformed by 34.81% the S&P500.

Envision Healthcare Corporation, through its subsidiaries, provides various healthcare services in the United States. The company has market cap of $5.34 billion. The firm operates through three reportable divisions: Physician Services, Medical Transportation, and Ambulatory Services. It has a 42.62 P/E ratio. The Company’s physician-led services encompass providers at approximately 1,500 clinical departments at healthcare facilities in 45 states and the District of Columbia that include emergency department and hospitalist, anesthesiology, radiology/tele-radiology, and children's services.

More notable recent Envision Healthcare Corporation (NYSE:EVHC) news were published by: which released: “Envision Healthcare To Go Private In $9.9B, All-Cash Deal” on June 11, 2018, also with their article: “Envision Healthcare (EVHC) Near Deal to Be Acquired by KKR” published on June 11, 2018, published: “INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Envision Healthcare …” on June 15, 2018. More interesting news about Envision Healthcare Corporation (NYSE:EVHC) were released by: and their article: “Reuters: HCA, KKR teaming on Envision buyout bid; EVHC +7.8%” published on May 18, 2018 as well as‘s news article titled: “Bragar Eagel & Squire, PC is Investigating the Board of Directors of Envision Healthcare Corporation (EVHC) on Behalf …” with publication date: June 11, 2018.

Envision Healthcare Corporation (NYSE:EVHC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: